About
Team
Investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
Corporate Governance
Shareholder Services
Analyst Coverage
Pipeline
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Avexitide for Congenital Hyperinsulinism (HI)
Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
ZOKINVY
®
Resources
Zokinvy® European SmPC
Expanded Access Policy
Contact Us
Privacy Policy
Social Media Guidelines
Terms and Conditions
Careers
About
Team
Investors
Stock Information
Press Releases
Events & Presentations
SEC Filings
Corporate Governance
Shareholder Services
Analyst Coverage
Pipeline
Avexitide for Post-Bariatric Hypoglycemia (PBH)
Avexitide for Congenital Hyperinsulinism (HI)
Lonafarnib / Ritonavir for Hepatitis Delta Virus (HDV) Infection
ZOKINVY
®
Resources
Zokinvy® European SmPC
Expanded Access Policy
Contact Us
Privacy Policy
Social Media Guidelines
Terms and Conditions
Careers
Results
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH)
Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress™ 2019
Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
Eiger BioPharmaceuticals Reports on 2018 R&D Day
Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
Modal Template